Moody Aldrich Partners’s Viridian Therapeutics VRDN Stock Holding History

Moody Aldrich Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-95,235	Closed	-$1.86M	–	220
2026 Q1	$1.86M	Sell	95,235 -952	-1%	-$28.3K	0.34%	111
2025 Q4	$2.99M	Buy	96,187 +22,074	+30%	+$605K	0.56%	81
2025 Q3	$1.6M	Sell	74,113 -15,051	-17%	-$271K	0.3%	108
2025 Q2	$1.25M	Buy	89,164 +31,323	+54%	+$425K	0.24%	109
2025 Q1	$780K	Sell	57,841 -847	-1%	-$14.4K	0.16%	112
2024 Q4	$1.13M	Buy	+58,688	New	+$1.28M	0.21%	113
2023 Q3	–	Sell	-57,451	Closed	-$1.37M	–	216
2023 Q2	$1.37M	Sell	57,451 -41,975	-42%	-$1.08M	0.27%	106
2023 Q1	$2.53M	Buy	99,426 +40,515	+69%	+$1.3M	0.51%	76
2022 Q4	$1.72M	Buy	+58,911	New	+$1.36M	0.35%	96

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Moody Aldrich Partners's VRDN Position: Q2 2026 in Review

Moody Aldrich Partners sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 95,235 shares — an estimated $1.86M sold.

Moody Aldrich Partners first reported a position in VRDN in Q4 2022 and held it in 9 quarters. The position peaked at $2.99M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Moody Aldrich Partners reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Moody Aldrich Partners sold 95,235 Viridian Therapeutics shares in Q2 2026, an estimated $1.86M.
Moody Aldrich Partners first reported a position in Viridian Therapeutics in Q4 2022 and held it in 9 quarters.
Moody Aldrich Partners's Viridian Therapeutics position peaked at $2.99M in Q4 2025.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.